Thursday, 12 November 2026European Markets

European Central Banking

3 articles

Central Bank Gold Reserves Hit $4 Trillion, Overtaking US Treasuries for First Time

Central Bank Gold Reserves Hit $4 Trillion, Overtaking US Treasuries for First Time

Global central bank gold holdings reached $4 trillion at the start of 2026, surpassing US Treasury holdings of $3.9 trillion — a historic first. The 2022 freeze of Russian reserves triggered a wholesale reassessment of foreign custody risk, accelerating European gold repatriation. Dollar weakness and mounting pressure on the Fed are deepening the shift.

LM Salvado•
ECB Signals June Rate Hike as Inflation Risks Worsen; European Institutions Race Into Tokenized Finance

ECB Signals June Rate Hike as Inflation Risks Worsen; European Institutions Race Into Tokenized Finance

ECB Governing Council member Christodoulos Patsalides warned this week that inflation risks are worsening in the eurozone, pointing directly toward a June rate hike. The stance mirrors the US, where Fed futures now assign only a one-in-three chance of any 2026 rate cut following Jerome Powell's departure. European institutions are simultaneously accelerating into tokenized finance, with central banks backing euro-denominated stablecoins even as policy tightens.

LM Salvado•
ECB Officials Prioritize Inflation Fight Over Growth as Middle East Conflict Threatens Price Stability

ECB Officials Prioritize Inflation Fight Over Growth as Middle East Conflict Threatens Price Stability

European Central Bank policymakers are signaling an extended pause in rate cuts as geopolitical risks from the Middle East conflict threaten to push inflation expectations higher. ECB Governing Council members Joachim Nagel and Luis de Guindos have identified inflation as a bigger concern than economic growth, while the Federal Reserve's Beth Hammack echoes similar caution about prolonged policy holds.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com